Skip to main content
. 2017 Apr 20;22(4):654. doi: 10.3390/molecules22040654

Table 3.

Effects of COS on the oral bioavailability of caffeic acid derivatives in the FLJ-FF herb couple preparations (Mean ± SD, n = 6).

Components Shuang-Huang-Lian Oral Liquid Yin-Qiao-Jie-Du Oral Liquid Fufang Qin-Lan Oral Liquid Qin-Re-Jie-Du Oral Liquid
Caffeic Acid Derivatives AUC (Control) AUC (Absorption Enhancer) Ratio AUC (Control) AUC (Absorption Enhancer) Ratio AUC (Control) AUC (Absorption Enhancer) Ratio AUC (Control) AUC (Absorption Enhancer) Ratio
Neochlorogenic acid 10,646 ± 1009.8 81,789 ± 9230.3 ** 7.6829 16,217 ± 2946.9 27,324 ± 3763.5 ** 1.6850 7706.5 ± 1066.0 28,664 ± 2028.7 ** 3.7195 16,826 ± 4489.8 25,208 ± 2157.4 * 1.4982
Chlorogenic acid 38,279 ± 5334.8 26,428 × 10 ± 40,480 ** 6.9041 43,537 ± 5549.5 97,656 ± 16040 ** 2.2431 22,643 ± 4304.1 62,547 ± 3675.1 ** 2.7623 44,095 ± 14,327 58,100 ± 2892.1 * 1.3176
Cryptochlorogenic acid 14,240 ± 1448.9 73,548 ± 7090.8 ** 5.1648 17,123 ± 1294.8 30,770 ± 6347.8 ** 1.7970 6771.0 ± 1078.0 18,832 ± 2037.5 ** 2.7813 23,515 ± 4239.6 40,972 ± 754.48 ** 1.7423
3,5-dicaffeoylquinic acid 3460.5 ± 260.90 16,812 ± 3170.7 * 4.8583 1730.3 ± 28.868 4278.5 ± 686.84 ** 2.4728 1889.6 ± 324.64 2911.3 ± 359.13 * 1.5407 2617.8 ± 697.59 6460.0 ± 968.28 ** 2.4678
3,4-dicaffeoylquinic acid 814.80 ± 84.113 1627.5 ± 9.1924 * 1.9974 1383.0 ± 114.56 2769.8 ± 13.435 ** 2.0027 847.53 ± 151.80 1955.8 ± 210.57 ** 2.3077 480.73 ± 54.438 1313.0 ± 192.84 ** 2.7313
Isoforsythoside 2711.0 ± 226.46 8080.0 ± 941.16 ** 2.9805 2012.2 ± 65.200 4343.3 ± 313.96 * 2.1585 2393.8 ± 129.40 2667.0 ± 156.62 1.1142 5516.7 ± 537.39 6750.7 ± 292.74 * 1.2237
Forsythoside A 11,776 ± 272.44 21,906 ± 369.82 * 1.8602 15,629 ± 2641.4 23,727 ± 1224.0 * 1.5182 5581.0 ± 591.26 11,555 ± 1131.1 ** 2.0703 10,438 ± 1181.5 13,446 ± 354.66 ** 1.2882
Forsythoside B 3685.0 ± 328.86 14,694 ± 2047.0 ** 3.9875 6678.3 ± 850.79 12,440 ± 1564.9 ** 1.8628 1416.5 ± 252.44 1868.2 ± 142.50 * 1.3189 1955.0 ± 716.78 2532.0 ± 183.95 1.2951
Integration 7294.0 ± 613.83 25,748 ± 355.67 ** 3.5300 9139.0 ± 1668.6 16,865 ± 1202.1 * 1.8454 5283.0 ± 653.58 12,811 ± 2545.9 ** 2.4249 9904.0 ± 886.13 14,818 ± 2331.3 * 1.4962

(*) p < 0.05 and (**) p < 0.01, compared with control group.

HHS Vulnerability Disclosure